Intercept Pharmaceuticals gets ODD for fixed dose of OCA-bezafibrate to treat PBC

Image: Intercept focuses on the development and commercialisation of new therapeutics to treat progressive non-viral liver diseases. Credit: Ewa Urban from Pixabay.